EXEL Exelixis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXEL

Price (delayed)

$55.85

Market cap

$14.04B

P/E Ratio

17.9

Dividend/share

N/A

EPS

$3.12

Enterprise value

$13.98B

?
Relative Growth: Rel. Growth: 95
Relative Strength: Rel. Strength: 74
Relative Valuation: Rel. Valuation: 68
Relative Profitability: Rel. Profitability: 98

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work ...

Highlights
The company's EPS rose by 39% YoY and by 8% QoQ
The company's net income rose by 30% YoY and by 6% QoQ
The P/E is 35% below the 5-year quarterly average of 27.6 but 8% above the last 4 quarters average of 16.6
The company's equity fell by 10% QoQ and by 9% YoY
EXEL's quick ratio is down by 10% since the previous quarter and by 9% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.exelixis.com
Peers: MRK BMY AMGN CRIS

Key stats

What are the main financial stats of EXEL

EXEL stock price

How has the Exelixis stock price performed over time
Intraday
3.5%
1 week
4.92%
1 month
15.06%
1 year
26.07%
YTD
27.42%
QTD
2.65%

Financial performance

How have Exelixis's revenue and profit performed over time
Revenue
$2.38B
Gross profit
$2.29B
Operating income
$936.67M
Net income
$833.42M
Gross margin
96.4%
Net margin
35.1%
The company's net income rose by 30% YoY and by 6% QoQ
The net margin has increased by 25% YoY and by 4.2% from the previous quarter
Exelixis's operating income has increased by 23% YoY and by 7% QoQ
EXEL's operating margin is up by 19% year-on-year and by 4.8% since the previous quarter

Price vs fundamentals

How does EXEL's price correlate with its fundamentals

Growth

What is Exelixis's growth rate over time

Valuation

What is Exelixis stock price valuation
EXEL P/E details
P/E
17.9
P/B
7.49
P/S
6.07
EV/EBIT
13.94
EV/EBITDA
13.24
EV/Sales
5.89
The company's EPS rose by 39% YoY and by 8% QoQ
The P/E is 35% below the 5-year quarterly average of 27.6 but 8% above the last 4 quarters average of 16.6
EXEL's P/B is 108% above its 5-year quarterly average of 3.6 and 34% above its last 4 quarters average of 5.6
The company's equity fell by 10% QoQ and by 9% YoY
EXEL's price to sales (P/S) is 45% higher than its 5-year quarterly average of 4.2 and 21% higher than its last 4 quarters average of 5.0
The revenue has grown by 3.3% YoY and by 2.4% from the previous quarter

Efficiency

How efficient is Exelixis business performance
The company's return on equity rose by 37% YoY and by 9% QoQ
The ROA has grown by 37% YoY and by 9% from the previous quarter
The ROIC has grown by 33% YoY and by 10% from the previous quarter
The company's return on sales rose by 16% YoY and by 3.9% QoQ

Dividends

What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXEL.

Financial health

How did Exelixis financials performed over time
EXEL's quick ratio is down by 10% since the previous quarter and by 9% year-on-year
The company's total assets fell by 9% QoQ and by 9% YoY
The debt is 91% less than the equity
The company's debt to equity rose by 13% QoQ
The company's equity fell by 10% QoQ and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.